糖尿病治療薬の世界市場及びパイプラインインサイト:1型糖尿病、2型糖尿病、糖尿病性足部潰瘍、糖尿病黄斑浮腫、糖尿病性胃アトニー、糖尿病網膜症

◆英語タイトル:Global Diabetes Drug Market & Pipeline Insight 2015
◆商品コード:KUICK504093
◆発行会社(調査会社):KuicK Research
◆発行日:2015年4月
◆ページ数:1100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,400 ⇒換算¥271,200見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD4,800 ⇒換算¥542,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、糖尿病治療薬の世界市場について調査・分析し、糖尿病治療薬の世界市場概要、市場の動態、市場展望、糖尿病治療薬(1型糖尿病、2型糖尿病、糖尿病性足部潰瘍、糖尿病黄斑浮腫、糖尿病性胃アトニー、糖尿病網膜症)のパイプライン動向、主要企業分析等の情報をお届けいたします。
【レポートの概要】

Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criterias set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.

Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn’t seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.

Several molecules belonging to different classes like carbohydrate digestion inhibitors, sulphonyl urea, insulin sensitizers and others are being screened for their effects on diabetes. They have to prove their candidature by providing better safety and efficacy profiles than existing diabetes drugs. Rigorous clinical trials would be required to prove their pharmacological worthiness for effectively treating diabetes patients. These molecules are known to have cytotoxicity due to which they may have side effects but by modulating its design such problems could be overcome by investigators. On the other hand, these molecules are easy to produce and offer higher cost effectiveness due to which pharmaceutical companies have become interested in their research and development. In coming years, more molecules of these types are expected to enter in global market which would be affordable by large number of patients belonging to different socio-economic groups.

Besides screening of novel molecules, emphasis on discovering different pathways have been given by investigators for developing diabetes drugs with higher safety and efficacy profiles. Insulin pathway is one of the most studied pathways that have been widely targeted by investigators to maintain blood glucose levels. Diabetes drugs that target cellular receptors have been made which works at molecular levels because they have higher control over insulin regulation. Some drug molecules increase the glucose uptake in cells to decrease blood glucose levels. On the other hand, there are diabetes drugs that act on the gastrointestinal tract and prevent the carbohydrate digestion in the body. Investigators have developed many methods to control diabetes and several innovative mechanisms are being studied to come forth with better products. As a result, more products will be launched due to which their market penetration is expected to increase in coming years.

Diabetes Indication in Report:

• Diabetic Neuropathies
• Diabetic Nephropathies
• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus
• Diabetic Foot Ulcer
• Diabetic Macular Oedema
• Diabetic Gastroparesis
• Diabetic Retinopathy
• Diabetes Insipidus
• Prediabetic State

“Global Diabetes Drug Market & Pipeline Insight 2015″ Report Highlight:

• Global Diabetes Drug Market Overview
• Global Diabetic Drug Clinical Pipeline by Company & Phase
• Global Diabetic Drug Clinical Pipeline: 817 Drugs
• Majority in Preclinical Phase: 205 Drugs
• Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
• Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
• Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
• Marketed Diabetic Drugs: 99 Drugs

【レポートの目次】

1. Introduction to Diabetes

2. Diabetes Drug Mechanism

3. Global Diabetes Drug Market Overview
3.1 Current Market Scenario
3.2 Global Diabetes Drug Pipeline Overview

4. Global Diabetes Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Development & Commercialization Challenges

5. Global Diabetes Drug Market Future Prospects

6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase
6.1 Research to till Registered
6.2 Marketed Drug Clinical Insight

7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase
7.1 Research to till Registered
7.2 Marketed Drug Clinical Insight

8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
8.1 Phase Research to till Registered
8.2 Marketed Drug Clinical Insight

9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
9.1 Research to till Registered
9.2 Marketed Drug Clinical Insight

10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
10.1 Research to till Registered
10.2 Marketed Drug Clinical Insight

11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase
11.1 Research to till Phase-III
11.2 Marketed Drug Clinical Insight

12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase
12.1 Research to till Registered
12.2 Marketed Drug Clinical Insight

13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase
13.1 Preclinical to till Phase-III
13.2 Marketed Drug Clinical Insight

14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase
14.1 Research to till Phase-III

15. Prediabetic State Drug Clinical Pipeline by Company & Phase
15.1 Phase-II

16. Diabetes Drug Clinical Pipeline by Company & Phase
16.1 Research to till Registered
16.2 Marketed Drug Clinical Insight

17. Competitive Landscape
17.1 AstraZeneca
17.2 Boehringer Ingelheim
17.3 Eli Lily
17.4 GalaxoSmithKline
17.5 Johnson & Johnson
17.6 MannKind Corporation
17.7 Merck
17.8 Novartis
17.9 Pfizer
17.10 Sanofi

1. Introduction to Diabetes

2. Diabetes Drug Mechanism

3. Global Diabetes Drug Market Overview
3.1 Current Market Scenario
3.2 Global Diabetes Drug Pipeline Overview

4. Global Diabetes Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Development & Commercialization Challenges

5. Global Diabetes Drug Market Future Prospects

6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase
6.1 Research to till Registered
6.2 Marketed Drug Clinical Insight

7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase
7.1 Research to till Registered
7.2 Marketed Drug Clinical Insight

8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
8.1 Phase Research to till Registered
8.2 Marketed Drug Clinical Insight

9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
9.1 Research to till Registered
9.2 Marketed Drug Clinical Insight

10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
10.1 Research to till Registered
10.2 Marketed Drug Clinical Insight

11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase
11.1 Research to till Phase-III
11.2 Marketed Drug Clinical Insight

12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase
12.1 Research to till Registered
12.2 Marketed Drug Clinical Insight

13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase
13.1 Preclinical to till Phase-III
13.2 Marketed Drug Clinical Insight

14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase
14.1 Research to till Phase-III

15. Prediabetic State Drug Clinical Pipeline by Company & Phase
15.1 Phase-II

16. Diabetes Drug Clinical Pipeline by Company & Phase
16.1 Research to till Registered
16.2 Marketed Drug Clinical Insight

17. Competitive Landscape
17.1 AstraZeneca
17.2 Boehringer Ingelheim
17.3 Eli Lily
17.4 GalaxoSmithKline
17.5 Johnson & Johnson
17.6 MannKind Corporation
17.7 Merck
17.8 Novartis
17.9 Pfizer
17.10 Sanofi


【掲載企業】

AstraZeneca, Boehringer Ingelheim, Eli Lily, GalaxoSmithKline, Johnson & Johnson, MannKind Corporation, Merck, Novartis, Pfizer, Sanofi


【レポートのキーワード】

糖尿病治療薬、1型糖尿病、2型糖尿病、糖尿病性足部潰瘍、糖尿病黄斑浮腫、糖尿病性胃アトニー、糖尿病網膜症、治療、医薬品、パイプライン

★調査レポート[糖尿病治療薬の世界市場及びパイプラインインサイト:1型糖尿病、2型糖尿病、糖尿病性足部潰瘍、糖尿病黄斑浮腫、糖尿病性胃アトニー、糖尿病網膜症] (コード:KUICK504093)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病治療薬の世界市場及びパイプラインインサイト:1型糖尿病、2型糖尿病、糖尿病性足部潰瘍、糖尿病黄斑浮腫、糖尿病性胃アトニー、糖尿病網膜症]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆